BioSenic S.A.

Transparency notifications received from François Rieger

  PRESS RELEASE – REGULATED INFORMATION

Article 14 of the Law of 2 May 2007 on disclosure of major holdings

Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger. Details of the notifications can be found below and the full versions of the transparency declarations are available on BioSenic's website, under the heading “Major shareholders & transparency notices”.

The transparency notification indicates that the shareholdings held by François Rieger have crossed below the threshold of 10% as a result of the issuance of new shares of BioSenic on 29 March 2024.

The notification received from François Rieger dated 5 April 2024 contains the following information:

• Reason for the notification:
• Passive crossing of a threshold
• Notification by: A person that notifies alone
• Person subject to the notification requirement: François Rieger
• Transferor of voting rights: François Rieger
• Transaction date: 29 March 2024
• Threshold that is crossed: 10%
• Denominator: 192 873 548
• Notified details:
  
  

Voting rights	Previous notification	After the transaction
Holders of voting rights	# of voting rights	# of voting rights	% of voting rights
François Rieger	18 589 361	18 589 361	9.64%
Total voting rights		18 589 361	9.64%

About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic’s arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).
Following the merger in October 2022, BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).